Working on getting a bibliography of sorts for psychedelic ethics/philosophy papers together - sharing in case it comes in useful for anyone else!
Ongoing project & please feel free to let me know if I've missed something 🌿
https://t.co/GpUL2a5XIn
JHU PhD student Katherine Cheung and PhD Candidate Caleigh Propes, with CPCR Associate Professor Dr. David Yaden, evaluated comparison sets on the price of Oregon’s psilocybin services. As the first state in the U.S. to legalize psilocybin access and a key reference point on how other states might design psychedelic policy, this exploration helps ground discussion on Oregon’s prices in more careful analysis for future debates.
https://t.co/H4y826EzPO
Drs. Fred Barrett and David Yaden have received a 2026 Johns Hopkins Nexus Award alongside fellow JHU scientists, educators, bioethicists, and economists. Their convening will bring together leaders across clinical, ethical, economic, and public health fields to advance critical conversations around the future of psychedelic policy. As the science matures, so must the policy conversations around it, and we are grateful to Johns Hopkins for supporting that work. https://t.co/ncln2h9cN2
Overall, by trying to make some of these comparison sets explicit, we hope to ground debates about Oregon’s prices in more careful analysis rather than intuition alone.
Oregon’s psilocybin services (~$3000 at the higher end) are often described as quite expensive. But when making this claim, we should ask: expensive compared to what?
https://t.co/oalSerULFO
There may be no “right” comparison. & psilocybin services may also strike people as expensive simply because their price puts them out of reach for many.
People claim that psychedelics have been used by Indigenous groups around the world for millennia. But clear evidence of serotonergic psychedelic use – even psilocybin – has long been confined to the Americas.
Until now. In a new preprint summarizing months of fieldwork, my collaborators and I systematically show that people in Lesotho use native psilocybin mushrooms for many different purposes, and have potentially been doing so for a very long time. 🧵
https://t.co/PXE07NK7ur
Led by @briandavidearp, the latest part of a scholarly exchange with Daniel Villiger on psychedelic exceptionalism!
Daniel's piece here: https://t.co/0IO6r12zj6
New 🚨 "Psychedelics Are Still Not Ethically Exceptional: Rebutting Recent Claims of Uniqueness" -- new work forthcoming in Neuroethics by myself, Katherine Cheung, and David Yaden. Part of a scholarly exchange with our friend and colleague Daniel Villiger. Apologies for the generic AI image from ChatGPT. LINK: https://t.co/ALDyAkDyCJ
New 🚨 "Psychedelics Are Still Not Ethically Exceptional: Rebutting Recent Claims of Uniqueness" -- new work forthcoming in Neuroethics by myself, Katherine Cheung, and David Yaden. Part of a scholarly exchange with our friend and colleague Daniel Villiger. Apologies for the generic AI image from ChatGPT. LINK: https://t.co/ALDyAkDyCJ
New findings from a pilot randomized trial of psilocybin for smoking cessation are now published in @JAMANetworkOpen. This is one of the largest controlled trials of psilocybin for substance use disorder, with promising results! Full paper linked below.